TIMOTHY DWIGHT, Ph.D.
Head of Chemistry
Tim is a medicinal chemist with over 10 years of experience in the pharmaceutical industry. Early in his career, Tim contributed to the development of Brigatinib, a treatment for ALK+ non-small cell lung cancer while at Ariad Pharmaceuticals. He then went on to co-invent a nominated CFTR corrector which could be used in combination with Ivacaftor and potentially help patients homozygous for F508del at Vertex Pharmaceuticals.
After moving to Silicon Therapeutics, he led medicinal chemistry efforts for the development of SNX281; a novel STING agonist that is currently undergoing clinical trials for the treatment of solid tumors. Most recently he led the chemistry strategy of a program focused on targeted protein degradation.